Last reviewed · How we verify
NCT04757571
The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients
Phase 1, PHASE2 trial testing Paroxetine in Rheumatoid Arthritis. Withdrawn.
31 December 2024
Quick facts
| Lead sponsor | Sadat City University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Start date | 1 February 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Paroxetine — full drug profile →
- Placebo
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Sadat City University
Who can join
Adults 18 to 60, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Among three MAPK families, paroxetine was found to be able to decrease the phosphorylation of ERK. It was reported that paroxetine attenuates the symptoms of collage induced arthritis rats due to its inhibitory effect on T cell activation and infiltration to synovial tissue via suppression of ERK pathway. This study aimed to evaluate the therapeutic efficacy of paroxetine in rheumatoid arthritis. Paroxetine prevents the joint inflammation which is at the very early stage. paroxetine could inhibit GRK2 with selectivity over other GRKs. Medications developed for maintaining the immunologic equilibrium. such as GRK2 inhibitors, will be the novel trends in RA treatment that could avoid the adverse side effects that are common with current treatment options.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Network-based stage-specific drug repurposing for Alzheimer's disease.
Savva K, Zachariou M, Bourdakou MM, Dietis N, et al · · 2022 · cited 24× · PMID 35386099 · DOI 10.1016/j.csbj.2022.03.013
Verify or expand the search:
- PubMed search for NCT04757571
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Paroxetine
Trials testing the same drug.
- NCT06763484 — Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause · Phase 2 · completed
- NCT06232109 — Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects · Phase 1 · completed
- NCT06231745 — Paroxetine Safety and Efficacy in Rheumatoid Arthritis · Phase 3 · recruiting
- NCT06049797 — A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats · active not recruiting
- NCT06065735 — Concentration-QT Study of Paroxetine in Healthy Adults · Phase 1 · completed
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Sadat City University trials
Trials by the same sponsor.
- NCT06546111 — Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With · Phase 1, PHASE2 · recruiting
- NCT06302049 — Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis · Phase 1, PHASE2 · recruiting
- NCT04433988 — Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients · Phase 1, PHASE2 · withdrawn
- NCT05433402 — Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer · Phase 1, PHASE2 · withdrawn
- NCT05453916 — Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipa · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04757571 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sadat City University
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04757571.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing